151 related articles for article (PubMed ID: 29781343)
1. Issues and promises of bevacizumab in prostate cancer treatment.
Cereda V; Formica V; Roselli M
Expert Opin Biol Ther; 2018 Jun; 18(6):707-717. PubMed ID: 29781343
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab treatment of prostate cancer.
Small AC; Oh WK
Expert Opin Biol Ther; 2012 Sep; 12(9):1241-9. PubMed ID: 22775507
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.
McKay RR; Zurita AJ; Werner L; Bruce JY; Carducci MA; Stein MN; Heath EI; Hussain A; Tran HT; Sweeney CJ; Ross RW; Kantoff PW; Slovin SF; Taplin ME
J Clin Oncol; 2016 Jun; 34(16):1913-20. PubMed ID: 27044933
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
7. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
8. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
11. Targeting Angiogenesis in Prostate Cancer.
Melegh Z; Oltean S
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151317
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics.
Polotti CF; Kim CJ; Chuchvara N; Polotti AB; Singer EA; Elsamra S
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1265-1273. PubMed ID: 29137489
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
14. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Bender RJ; Mac Gabhann F
BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
[TBL] [Abstract][Full Text] [Related]
16. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
Jang HS; Koo KC; Cho KS; Chung BH
Yonsei Med J; 2016 Sep; 57(5):1070-8. PubMed ID: 27401636
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis and anti-angiogenic therapy in prostate cancer.
Mukherji D; Temraz S; Wehbe D; Shamseddine A
Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
20. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
